

# Primary care



This is an abridged version; the full version is on [bmj.com](http://bmj.com)

## Iron supplementation for unexplained fatigue in non-anaemic women: double blind randomised placebo controlled trial

F Verdon, B Burnand, C-L Fallab Stubi, C Bonard, M Graff, A Michaud, T Bischoff, M de Vevey, J-P Studer, L Herzig, C Chapuis, J Tissot, A Pécoud, B Favrat

General Practice Unit, University of Lausanne, rue du Bugnon 44, 1011 Lausanne, Switzerland

F Verdon  
general practitioner

C Bonard  
general practitioner

M Graff  
general practitioner

A Michaud  
general practitioner

T Bischoff  
general practitioner

M de Vevey  
general practitioner

J-P Studer  
general practitioner

L Herzig  
general practitioner

C Chapuis  
general practitioner

J Tissot  
general practitioner

Health Care Evaluation Unit, Institute of Social and Preventive Medicine, University of Lausanne

B Burnand  
senior lecturer

Medical Outpatient Clinic, University of Lausanne

C-L Fallab Stubi  
pharmacist

A Pécoud  
professor

B Favrat  
consultant of internal medicine

Correspondence to: B Favrat  
[bernard.favrat@hospvd.ch](mailto:bernard.favrat@hospvd.ch)

BMJ 2003;326:1124-6

### Abstract

**Objective** To determine the subjective response to iron therapy in non-anaemic women with unexplained fatigue.

**Design** Double blind randomised placebo controlled trial.

**Setting** Academic primary care centre and eight general practices in western Switzerland.

**Participants** 144 women aged 18 to 55, assigned to either oral ferrous sulphate (80 mg/day of elemental iron daily; n=75) or placebo (n=69) for four weeks.

**Main outcome measures** Level of fatigue, measured by a 10 point visual analogue scale.

**Results** 136 (94%) women completed the study. Most had a low serum ferritin concentration;  $\leq 20 \mu\text{g/l}$  in 69 (51%) women. Mean age, haemoglobin concentration, serum ferritin concentration, level of fatigue, depression, and anxiety were similar in both groups at baseline. Both groups were also similar for compliance and dropout rates. The level of fatigue after one month decreased by  $-1.82/6.37$  points (29%) in the iron group compared with  $-0.85/6.46$  points (13%) in the placebo group (difference 0.95 points, 95% confidence interval 0.32 to 1.62;  $P=0.004$ ). Subgroups analysis showed that only women with ferritin concentrations  $\leq 50 \mu\text{g/l}$  improved with oral supplementation.

**Conclusion** Non-anaemic women with unexplained fatigue may benefit from iron supplementation. The effect may be restricted to women with low or borderline serum ferritin concentrations.

### Introduction

Although the symptom of fatigue is related to iron deficiency anaemia, evidence is lacking for any association between iron deficiency and tiredness in the absence of anaemia. In a European study, about 20% of women of childbearing age had a serum ferritin concentration less than  $15 \mu\text{g/l}$ , and only 4% of these women had iron deficiency anaemia.<sup>1</sup> We examined the effect of iron therapy in women with unexplained fatigue in the absence of anaemia.

### Methods

Our study was conducted in a primary care setting. Participants were recruited from December 1997 to March 2000. Women aged 18 to 55 were included if their main reason for consulting was fatigue. We excluded women with anaemia (haemoglobin concentration  $< 117 \text{ g/l}$ ), other obvious physical or psychiatric cause for fatigue, or chronic fatigue syndrome. Reasons for late exclusions had been determined beforehand: pregnancy diagnosed during the study period, haemochromatosis, physical or mental disorders identified after inclusion, and vitamins or iron supplements taken during the trial.

### Randomisation, main outcome, and adherence to treatment

Our study was a pragmatic randomised placebo controlled trial. Participants received either 80 mg/day oral long acting ferrous sulphate (Tardyferon; Robapharm) or placebo for four weeks. Iron and placebo were identical in appearance and taste and dose regimen. Randomisation took place at an independent pharmacy, according to a pre-established list. Patients, caregivers, and investigators were blinded to treatment assignment until the end of the trial. Each drug package was coded with a unique number according to the randomisation schedule and then posted to the relevant practice.

The main outcome was the level of fatigue perceived by patients, assessed at baseline and after one month on a 10 point visual analogue scale, ranging from 1 (no fatigue at all) to 10 (very severe fatigue). Also used was a validated 24 item self administered questionnaire incorporating eight items for each of three dimensions (fatigue, anxiety, and depression).<sup>2</sup> Each item was scored on a visual analogue scale. A cumulative score was obtained for each dimension by adding the eight item scores (range 0-40). The patients were asked about any potential side effects and intercurrent physical, psychological, and haemorrhagic events. Serum ferritin concentration and adherence to treatment were measured and considered as intervening variables. A complete blood count and serum ferritin concentration were obtained at baseline. Clinicians could order other tests to rule out any disorder.

Change in level of fatigue after one month in women receiving iron or placebo for unexplained fatigue in absence of anaemia. Values are means (standard deviations) unless stated otherwise

Type of therapy	No of women	Level of fatigue*				
		Baseline	One month	Decrease	Difference (95% CI)	P value
Iron	71	6.4 (1.6)	4.5 (1.9)	1.82 (1.7)	0.97 (0.32 to 1.62)	0.004
Placebo	65	6.5 (1.5)	5.6 (2.2)	0.85 (2.1)		

\*Measured on visual analogue scale.

der to explain the fatigue. Serum ferritin concentration was measured after one month in those patients whose initial value was  $\leq 20$   $\mu\text{g/l}$ .

Adherence to treatment was measured by an electronic device, which recorded the date and time that the pill container was opened.<sup>3</sup> Unused pills were also counted. Patients were asked not to take over the counter vitamin or iron supplements.

### Statistical analysis

We calculated changes in symptom levels and scores over time for each patient. The principal analysis was performed according to an intention to treat protocol. Tests performed were two sample *t* tests,  $\chi^2$  tests, and linear regression analyses.

### Results

Of the 144 patients enrolled, 136 (94%) completed the intervention, seven (5%) were lost to follow up, and one withdrew because of nausea and vomiting. The iron group and the placebo group had similar characteristics at baseline. Low serum ferritin concentrations were common:  $\leq 50$   $\mu\text{g/l}$  in 115 (85%) patients and  $\leq 20$   $\mu\text{g/l}$  in 69 (51%) patients. Scores for anxiety and depression were low in both groups.

The mean decrease in the overall intensity of fatigue between zero and one month was higher in the iron group than in the placebo group (table). By choosing a cut-off point of 50  $\mu\text{g/l}$ , we found that there was no quantitatively significant response greater than 50  $\mu\text{g/l}$  ( $P=0.64$ ). The iron group showed the largest decrease in the cumulative score for fatigue ( $-7.5$  (8.0) *v*  $-4.6$  (7.5) points, difference 3.0 points, 0.3 to 5.6,  $P=0.03$ ). The difference for depression was not statistically different between the two groups ( $-2.1$  (6) *v*  $-1$  (7) points,  $P=0.31$ ), whereas a greater decrease in anxiety was observed in the iron group ( $-1.7$  (6) *v*  $1.3$  (6),  $P=0.003$ ).

After adjustment for age, initial levels of depression and anxiety, and serum ferritin concentration in a multiple linear regression analysis, iron supplementation was the most important variable to be associated with the decrease in the overall intensity of fatigue, an effect corresponding to  $-1$  point on the visual analogue scale. Younger age was also associated with a larger decrease in the intensity of fatigue.

A multiple linear regression analysis in the iron group showed that age, initial levels of depression and anxiety, serum ferritin concentration, and haemoglobin concentration were not predictive of the mean decrease in the overall intensity of fatigue. The best predictor of response was the amount of pills consumed in the iron group, but this was not so in the placebo group.

Compliance and dropout rates were similar in both groups: 95% (12) *v* 98% (9),  $P=0.25$  for compliance and 4 of 75 (5%) *v* 4 of 69 (6%) for drop-

out rates in the iron arm and placebo arm, respectively. After the intervention, serum ferritin concentrations were highest in the iron group (21.0 (SD 9.2) *v* 13.7 (6.9),  $P<0.001$ ).

### Discussion

To our knowledge this is the first randomised clinical trial in women of childbearing age to show that iron supplementation could have an effect on fatigue in the absence of anaemia. The effect may, however, be restricted to women with low or borderline serum ferritin concentrations. One trial found that 35 women with lassitude or poorly defined symptoms but without anaemia benefited from iron rather than placebo.<sup>4</sup> Adolescent females have been shown to benefit from iron supplementation: iron improved lassitude, ability to concentrate in school, and mood in one study, and in another study supplementation with 260 mg elemental iron daily improved verbal learning and memory.<sup>5,6</sup> In a non-randomised comparison of Australian women, fatigue decreased and quality of life increased with iron supplementation or a diet high in iron.<sup>7</sup>

Identifying iron deficiency without anaemia as a potential cause of fatigue is important. It may avoid the inappropriate attribution of symptoms to putative emotional causes or life stressors and thereby reduce unnecessary use of healthcare resources. Instituting iron therapy early may also improve quality of life.<sup>8</sup>

We found a significant response only in the patients with a baseline serum ferritin concentration  $\leq 50$   $\mu\text{g/l}$ . This suggests that iron deficiency could be present even with a "normal" concentration of serum ferritin. Indeed, the lower limit for serum ferritin concentration is controversial: iron stores in the bone marrow may serve as a better indicator of iron deficiency.<sup>9</sup> The lower reference limits for serum ferritin and haemoglobin concentrations have been considered too low for women and it has been suggested should be the same as for men.<sup>10</sup>

Iron deficiency even in the absence of anaemia is associated with decreased activity of iron dependent enzymes and therefore affects the metabolism of neurotransmitters.<sup>11,12</sup> In people with iron deficiency anaemia the related symptoms will disappear more quickly than the accompanying increase in haematological indices.<sup>13</sup> We did not, however, measure haemoglobin concentration after exposure to iron.

### Limitations of study

Firstly, blinding for group assignment is an important issue, especially with iron, because of the side effects. It was not possible to correct for the change in stool colour by adding bismuth to the placebo because bismuth is an active substance. To minimise the side effects we used a low dose iron sulphate taken with breakfast. Participants in both groups were also told that their

**What is already known on this topic**

Unexplained fatigue is common in young women

Iron deficiency is highly prevalent among women of childbearing age

Iron therapy is a well established treatment for fatigue in the presence of iron deficiency anaemia but not in the absence of anaemia

**What this study adds**

Iron supplementation may benefit women aged 18 to 55 years with unexplained fatigue in the absence of anaemia

The effect may, however, be restricted to women with low or borderline serum ferritin concentrations

drug could colour stools. We did not ask the participants to guess their group assignment. In a recent placebo controlled trial no significant differences in guesses about treatment were found between iron and placebo groups despite the elemental iron dose used being three times that of our study.<sup>6</sup> We found no difference in compliance between the two groups suggesting that the patients did not recognise that they had been assigned to placebo. Secondly, we did not have a procedure to control recruitment of all consecutive eligible patients, because this would have been difficult to apply in a busy clinical practice. Thirdly, ferritin concentration was the only measure of iron status in the study because it is considered the best non-invasive indicator of iron storage.<sup>14</sup> Finally, our primary outcome focused on fatigue, a patient centred subjective measure.

We thank M Burnier for his contribution to the electronic monitoring of patient compliance and for his critique of the

manuscript and W Ghali (University of Calgary, Alberta, Canada) for his comments on the revised manuscript.

Contributors: See [bmj.com](http://bmj.com)

Funding: This study was sponsored by Robapharm. The sponsor was not involved in the analysis of the results nor in writing or correcting the manuscript.

Competing interests: FV and BF received financial support from Robapharm for producing a preliminary report of the study.

Ethical approval: The study was approved by the ethical review committee for clinical research of the Department of Internal Medicine, University of Lausanne.

- 1 Galan P, Yoon H-C, Preziosi P, Viteri P, Fieux B, Briançon S, et al. Determining factors in the iron status of adult women in the SU.VI.MAX study. *Eur J Clin Nutr* 1998;52:383-8.
- 2 Pichot P, Brun JP. Questionnaire bref d'auto-évaluation des dimensions dépressive, athénique et anxieuse. *Ann Med Psychol* 1984;142:862-5.
- 3 Averbuch M, Weintraub M, Pollak DJ. Compliance assessment in clinical trials: the MEMS device. *J Clin Res Pharmacoevidemiol* 1990;4:199-204.
- 4 Beutler E, Larsh SE, Gurney CW. Iron therapy in chronically fatigued, nonanaemic women: a double-blind study. *Ann Intern Med* 1960;52:378-94.
- 5 Ballin A, Berar M, Rubinstein U, Kleter Y, Hershkovitz A, Meytes D. Iron state in female adolescents. *Am J Dis Child* 1992;146:803-5.
- 6 Bruner AB, Joffe A, Duggan A, Casella JE, Brandt J. Randomised study of cognitive effects of iron supplementation in non-anaemic iron-deficient girls. *Lancet* 1996;348:992-6.
- 7 Patterson AJ, Brown WJ, Roberts DC. Dietary and supplement treatment of iron deficiency results in improvements in general health and fatigue in Australian women of childbearing age. *J Am Coll Nutr* 2001;20:337-42.
- 8 Patterson AJ, Brown WJ, Powers JR, Roberts DC. Iron deficiency, general health and fatigue: results from the Australian longitudinal study on women's health. *Qual Life Res* 2000;9:491-7.
- 9 Hallberg L, Bengtsson C, Lapidus L, Lindstedt G, Lundberg PA, Hulten L. Screening for iron deficiency: an analysis based on bone-marrow examinations and serum ferritin determinations in a population sample of women. *Br J Haematol* 1993;85:787-98.
- 10 Rushton DH, Dover R, Sainsbury AW, Norris MJ, Gilkes JJ, Ramsay ID. Why should women have lower reference limits for haemoglobin and ferritin concentrations than men? *BMJ* 2001;322:1355-7.
- 11 Dallman PR. Iron deficiency: does it matter? *J Intern Med* 1989;226:367-72.
- 12 Scrimshaw NS. Functional consequences of iron deficiency in human populations. *J Nutr Sci Vitaminol* 1984;30:47-63.
- 13 Ohira Y, Edgerton VR, Gardner GW, Senewiratne RJ, Barnard RJ, Simpson DR. Work capacity heart rate and blood lactate response to iron treatment. *Br J Haematol* 1979;41:365-72.
- 14 Guyatt GH, Oxman AD, Ali M, Willan A, McLroy W, Patterson C. Laboratory diagnosis of iron-deficiency anaemia. *J Gen Intern Med* 1992;7:145-53.

(Accepted 20 March 2003)

*One hundred years ago***The prevention of juvenile smoking**

A Bill is to be introduced into Parliament "at the earliest possible date," under the auspices of the British Antitobacco and Antinicotine League, for the suppression of the use of tobacco by young persons under the age of 16. The main provisions of the Bill are the following: No person under the age of sixteen years shall smoke or use tobacco in any form, and any such person so doing shall be liable, on conviction, to a penalty not exceeding ten shillings for each offence. No person shall sell, give, or supply tobacco in any form to, or for the use of, any person under the age of sixteen years, and any person so doing shall be liable: (1) On a first conviction to a penalty not exceeding twenty shillings; (2) on a second or subsequent conviction to a penalty not exceeding forty shillings; and in addition to the foregoing penalties the licence (if any) held by such person for the sale of tobacco shall, in case of a third conviction, become void, and such person shall be disqualified for a term of five years from the date of such conviction from holding any such licence. . . . A single

wholesale firm of cigarette manufacturers who used to make and sell only a quarter of a million of cigarettes a week now disposes of five millions in the same period; and another wholesale firm which at one time had practically no business at all in this article, is now manufacturing no fewer than thirty millions of cigarettes a week . . .

In thirty-three of the States of the American Union attempts have been made by the Legislature to grapple with the evil. Enactments against juvenile smoking have also been passed in Canada, Tasmania, Bermuda, and Prince Edward Island. In Norway a similar measure was enacted not long ago. It is high time that something should be done in this country to prevent, or at least diminish, the evil effects of a habit which by undermining the strength of growing boys must, if allowed to continue unchecked, come to be a powerful factor in the decadence of the nation.

(*BMJ* 1903;i:687)